Personalis SEC Filings

Personalis, Inc. is asking stockholders to vote at its virtual 2026 annual meeting on May 12, 2026. Investors will elect two Class I directors, ratify BDO USA, P.C. as auditor for 2026, and approve on an advisory basis executive pay.

Holders of 104,677,900 common shares as of March 17, 2026 can vote online, by phone, mail, or during the webcast. The board is majority independent, led by an independent chair, and uses three key committees for audit, compensation, and governance oversight. The filing details major stockholders, director experience, and 2025 CEO pay of $3.5 million, including equity and performance-based bonus.

Personalis, Inc. CFO and COO Aaron Tachibana received new equity awards as compensation. He was granted stock options for 206,250 shares of common stock at an exercise price of $6.72 per share, expiring on March 15, 2036. These options vest in 36 equal monthly installments beginning on April 15, 2026.

He also received 34,375 restricted stock units, each representing one share of common stock upon settlement. These RSUs vest in six equal semi-annual installments, with the first tranche vesting on September 15, 2026. Following the RSU grant, he directly holds 198,833 shares of common stock.

Personalis, Inc. reported new equity awards to SVP and Chief Legal Officer Stephen Michael Moore. He received stock options for 168,750 shares of common stock at an exercise price of $6.72 per share, and 28,125 shares of common stock as restricted stock units.

The RSUs vest in six equal semi-annual installments starting on September 15, 2026. The stock options vest in 36 equal monthly installments beginning on April 15, 2026. After these grants, Moore directly holds 92,325 shares of common stock.

Personalis, Inc. Chief Executive Officer Christopher M. Hall reported equity awards consisting of new stock options and restricted stock units. He was granted options to buy 525,000 shares of common stock at an exercise price of 6.7200 per share, vesting in 36 equal monthly installments beginning on April 15, 2026, and expiring on March 15, 2036.

Hall also received 87,500 shares of common stock represented by restricted stock units, which vest in six equal semi-annual installments starting on September 15, 2026. Following the grant, his directly held common stock position reported in this filing is 235,986 shares. These are compensation-related awards rather than open-market purchases.

Personalis, Inc. reported that President and CMO Richard Chen received new equity awards. He was granted stock options for 281,250 shares of common stock at an exercise price of $6.72 per share, vesting in 36 equal monthly installments starting on April 15, 2026.

Chen also received 46,875 restricted stock units, each representing one share of common stock, vesting in six equal semi-annual installments beginning on September 15, 2026. Following these awards, he directly holds 173,880 shares of common stock.

Personalis, Inc. appointed Richard Chen as President, adding to his roles as Executive Vice President, R&D, and Chief Medical Officer. Christopher Hall previously served as President and remains Chief Executive Officer.

Chen’s annual base salary will increase to $570,000 effective April 1, 2026, with a performance bonus target set at 70% of his then-current base salary. On March 15, 2026, he will receive an option to purchase 37,500 shares of common stock at the March 13, 2026 closing price, vesting in equal monthly installments over 36 months, and a restricted stock unit award covering 6,250 shares, vesting over time starting six months after the grant date, in each case subject to continued service under the company’s 2019 Equity Incentive Plan.

Personalis, Inc. provides advanced cancer genomic testing services used by physicians and drug developers for minimal residual disease detection, recurrence monitoring, and therapy selection. Key offerings include NeXT Personal Dx and NeXT Dx, supported by a CLIA-certified, CAP-accredited lab in Fremont, California.

The company recently secured Medicare coverage for NeXT Personal Dx in Stage II–III breast cancer (effective October 7, 2025) and Stage I–III non-small cell lung cancer (effective January 9, 2026), plus earlier coverage for its NeXT Dx comprehensive genomic profiling test. Despite this progress, Personalis reported a net loss of $81.3 million in 2025 and an accumulated deficit of $631.3 million, and remains dependent on a concentrated customer base, notably Moderna and the VA Million Veteran Program.

Personalis, Inc. reported fourth quarter and full year 2025 results and issued 2026 guidance, highlighting rapid growth in its clinical testing business alongside continued losses. Full year 2025 revenue was $69.6 million, down from $84.6 million, with a net loss of $81.3 million. However, clinical test volume surged nearly 400% to 16,233 tests, and Q4 clinical test revenue rose to $0.9 million from $0.2 million. The company ended 2025 with about $240 million in cash, cash equivalents and short-term investments, including $109 million of ATM proceeds. For 2026, Personalis guides to revenue of $78–$80 million, clinical revenue of $10–$11 million on 43,000–45,000 tests, and expects a net loss of about $105 million and cash usage of about $100 million as it invests behind 5x projected clinical revenue growth.

Personalis, Inc. executive Aaron Tachibana, the company’s CFO and COO, reported an acquisition of derivative securities through equity compensation. On February 23, he became entitled to 15,000 stock options at an exercise price of $0.00 per share, held as direct ownership.

According to the disclosure, this amount reflects the vesting of a performance stock option originally granted on March 15, 2024, after a specified reimbursement milestone was satisfied. The filing records this as a grant or award-type acquisition rather than an open-market purchase or sale of Personalis common stock.